HCP1904
/ Hanmi
- LARVOL DELTA
Home
Next
Prev
1 to 10
Of
10
Go to page
1
October 08, 2024
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1904 in Healthy Male Volunteers.
(clinicaltrials.gov)
- P1 | N=16 | Completed | Sponsor: Hanmi Pharmaceutical Company Limited | Not yet recruiting ➔ Completed
Trial completion
September 22, 2023
Clinical Efficacy and Safety Evaluation of HCP1904-2 in Essential Hypertension Patients
(clinicaltrials.gov)
- P3 | N=122 | Completed | Sponsor: Hanmi Pharmaceutical Company Limited | Recruiting ➔ Completed
Trial completion • Cardiovascular • Hypertension
September 22, 2023
Clinical Efficacy and Safety Evaluation of HCP1904-1 in Essential Hypertension Patients
(clinicaltrials.gov)
- P3 | N=123 | Completed | Sponsor: Hanmi Pharmaceutical Company Limited | Recruiting ➔ Completed
Trial completion • Cardiovascular • Hypertension
September 22, 2023
Clinical Efficacy and Safety Evaluation of HCP1904-3 in Essential Hypertension Patients
(clinicaltrials.gov)
- P3 | N=166 | Completed | Sponsor: Hanmi Pharmaceutical Company Limited | Recruiting ➔ Completed
Trial completion • Cardiovascular • Hypertension
September 22, 2023
A Study to Evaluate the PK, Safety and Tolerability of HCP1803.
(clinicaltrials.gov)
- P1 | N=20 | Completed | Sponsor: Hanmi Pharmaceutical Company Limited | Not yet recruiting ➔ Completed
Trial completion
February 10, 2023
A Study to Evaluate the PK, Safety and Tolerability of HCP1803.
(clinicaltrials.gov)
- P1 | N=20 | Not yet recruiting | Sponsor: Hanmi Pharmaceutical Company Limited
New P1 trial
June 07, 2022
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1904 in Healthy Male Volunteers.
(clinicaltrials.gov)
- P1 | N=16 | Not yet recruiting | Sponsor: Hanmi Pharmaceutical Company Limited
New P1 trial
January 20, 2022
Clinical Efficacy and Safety Evaluation of HCP1904-3 in Essential Hypertension Patients
(clinicaltrials.gov)
- P3; N=158; Recruiting; Sponsor: Hanmi Pharmaceutical Company Limited
Clinical • New P3 trial • Hypertension
April 05, 2021
Clinical Efficacy and Safety Evaluation of HCP1904-2 in Essential Hypertension Patients
(clinicaltrials.gov)
- P3; N=116; Recruiting; Sponsor: Hanmi Pharmaceutical Company Limited
New P3 trial • Hypertension
March 29, 2021
Clinical Efficacy and Safety Evaluation of HCP1904-1 in Essential Hypertension Patients
(clinicaltrials.gov)
- P3; N=116; Recruiting; Sponsor: Hanmi Pharmaceutical Company Limited
New P3 trial • Hypertension
1 to 10
Of
10
Go to page
1